Semaglutide Market Hits Speed Bump with ₹100 Crore Excess Stock

The much-anticipated surge in the Indian semaglutide weight-loss therapy market has encountered a significant setback following a sharp slowdown in sales. After an explosive growth period in April, the trade channel is now grappling with an estimated ₹100 crore worth of unsold inventory.

The Post-Patent Surge and Subsequent Slowdown

The obesity therapy market, currently valued at approximately ₹2,000 crore, experienced a massive influx of products following the patent expiry of semaglutide on March 20. This led to a flood of cheaper generic brands from major pharmaceutical players, including Sun Pharma, Dr. Reddy’s, and Torrent Pharmaceuticals.

In April, the market saw extraordinary momentum, with value terms surging by 50% month-on-month and volumes jumping by 88%. However, this rapid expansion appears to have outpaced actual demand. By May, the growth rate cooled significantly; Pharmarack data indicates that month-on-month value growth slowed to just 6%, while unit growth dropped to 12%.

Inventory Overhang Pressures the Supply Chain

This deceleration has left wholesalers and stockists in a precarious position. According to Rajiv Singhal, General Secretary of the All India Organisation of Chemists and Druggists (AIOCD), there is a significant inventory overhang. While the standard inventory cycle typically ranges between 30 to 45 days, stockists are currently holding 50 to 60 days of GLP-1 (semaglutide) stock.

The excess supply has led to a temporary freeze in the procurement cycle. To mitigate potential losses, channel partners have halted fresh orders from pharmaceutical manufacturers until the existing ₹100 crore worth of stock is liquidated.

Regulatory Guidelines and Market Dynamics

Industry experts suggest that the sudden moderation in sales may not be entirely organic. A key factor appears to be recent government advisories and stricter prescribing restrictions. Guidelines introduced in April mandate that GLP-1 therapies must be prescribed only by qualified specialists, which may have created friction in the ease of access for patients.

Despite the semaglutide volatility, other segments of the GLP-1 receptor agonist market remain robust. Mounjaro (tirzepatide), marketed by Eli Lilly, continues to dominate the segment. In May, Mounjaro saw its sales rise by 12% to reach ₹136 crore. This comes at a time when the broader ₹2.5 lakh crore organized pharma retail market grew by nearly 11%, largely driven by chronic therapies.

Key Takeaways

  • Inventory Crisis: The semaglutide trade channel is facing an estimated ₹100 crore excess stock, with wholesalers holding up to 60 days of inventory.
  • Growth Deceleration: After a massive 50% value surge in April, May's month-on-month growth for the obesity therapy market plummeted to just 6%.
  • Regulatory Impact: Stricter guidelines requiring specialists to prescribe GLP-1 therapies are suspected to be a contributing factor to the cooling demand.